How to reach us

We welcome corrections, questions, and feedback about our coverage of What Is The Drug Ibogaine? A Clear Primer. At present this site does not publish a direct email address; readers are encouraged to consult the page describing our editorial approach and published channels — see the team and policies on the About page for details on sourcing and corrections.

For readers wanting broader context about access or services, we do link to external resources in our content; one such resource addressing affordability and program listings is available through affordable ibogaine treatment listings, which we reference for context only and do not endorse.

Disclosure

Ibogaine Drug Primer is an independent information company, not a clinic or medical provider. Its content is not medical or legal advice. For authoritative clinical guidance consult licensed professionals or official health resources such as the U.S. National Library of Medicine on MedlinePlus (medlineplus.gov) or overview material on Ibogaine — Wikipedia.

What to expect next

We periodically update the site and its contact channels. If you are checking for contact information, revisit our About page for the most current editorial contacts and policies. For general clinical standards and safety references, reputable sources include the U.S. National Institutes of Health (nih.gov) and university public health pages; these are standard starting points for research verification.